Heterogeneity in treatment effects across diverse populations.

Bridget M Nugent, Rajanikanth Madabushi, Barbara Buch, Vasum Peiris, Victor Crentsil, Virginia M Miller, Jonca Bull, Marjorie R Jenkins

Pharmaceutical statistics 2021 Sep

filter terms:

Differences in patient characteristics, including age, sex, and race influence the safety and effectiveness of drugs, biologic products, and medical devices. Here we provide a summary of the topics discussed during the opening panel at the 2018 Johns Hopkins Center for Excellence in Regulatory Science and Innovation symposium on Assessing and Communicating Heterogeneity of Treatment Effects for Patient Subpopulations: Challenges and Opportunities. The goal of this session was to provide a brief overview of FDA-regulated therapeutics, including drugs, biologics and medical devices, and some of the major sources of heterogeneity of treatment effects (HTE) related to patient demographics, such as age, sex and race. The panel discussed the US Food and Drug Administration's role in reviewing and regulating drugs, devices, and biologic products and the challenges associated with ensuring that diverse patient populations benefit from these therapeutics. Ultimately, ensuring diverse demographic inclusion in clinical trials, and designing basic and clinical research studies to account for the intended patient population's age, sex, race, and genetic factors among other characteristics, will lead to better, safer therapies for diverse patient populations. © 2021 John Wiley & Sons Ltd. This article has been contributed to by US Government employees and their work is in the public domain in the USA.

Citation

Bridget M Nugent, Rajanikanth Madabushi, Barbara Buch, Vasum Peiris, Victor Crentsil, Virginia M Miller, Jonca Bull, Marjorie R Jenkins. Heterogeneity in treatment effects across diverse populations. Pharmaceutical statistics. 2021 Sep;20(5):929-938